AHA Scientific Sessions 2026 Abstract·Nov 9A Case of Multidisciplinary Collaborative Care for Individualized Cardiovascular Risk Reduction After Adverse Pregnancy OutcomesCase reportAdverse pregnancy outcomesPaper
Revista Brasileira de Psiquiatria·Nov 6Drugs Associated with Dementia-Related Adverse Event Reports: A Real World Pharmacovigilance StudyComputational studyDementiaPaper
Frontiers in Cardiovascular Medicine·Oct 29Mechanisms and clinical outcomes of sacubitril-valsartan and SGLT2 inhibitors in heart failure patients: a retrospective cohort studyCohort study of 150 peopleSGLT2 inhibitorsPaper
ESC Congress 2026 Abstract·Oct 26Racial differences on treatment response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT TrialRandomized trial in 673 peopleUncontrolled hypertensionPaper
ESC Congress 2026 Abstract·Oct 26Impact of baseline cardiovascular risk on hypertension treatment with a novel triple single-pill: a subanalysis of the OPTION TREAT TrialRandomized trial in 666 peopleUncontrolled hypertensionPaper
ESC Congress 2026 Abstract·Oct 26Sex differences in response to triple single-pill combinations for hypertension: a secondary analysis of the OPTION TREAT TrialRandomized trial in 703 peopleHypertensionPaper
ESC Congress 2026 Abstract·Oct 26Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy: a nationwide cohort studyCohort study of 128,779 peopleAmlodipinePaper
ESC Congress 2026 Abstract·Oct 26Heart failure therapy optimization in myocardial infarction patients with systolic dysfunction during Phase 2 and 3 Cardiac RehabilitationCohort study of 87 peopleCardiac rehabilitationPaper
ESC Congress 2026 Abstract·Oct 26Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trialsStudy of 18,823 peopleInterventionsPaper
Journal of the American Heart Association·Oct 25Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic ReviewSystematic review of studies in peopleLeft ventricular hypertrophyPaper
Cureus·Oct 25Graves' Disease and the Heart: Severe Reversible Left Ventricular Systolic Dysfunction With Apical Thrombus in a Young Woman With Relapsed ThyrotoxicosisCase reportLeft ventricular systolic dysfunctionPaper
International Journal of Geriatrics·Oct 19Study of the effects of capsaicin-mediated regulation of the TGF-β1/Smad pathway on myocardial remodeling in aged hypertensive ratsExperiments in 60 ratsInterventionsPaper
Journal of Human Hypertension·Sep 15Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitusCohort study of 22,500 peopleTelmisartanPaper
Annals of Internal Medicine·Aug 3In symptomatic HF, sacubitril-valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 moTrial in peopleSacubitril + valsartanPaper
Pharmacogenetics and Genomics·Mar 20The potential effect and pathway of valsartan: genome-wide and phenome-wide association study from UK Biobank dataMendelian randomization in peopleValsartanPaper
Current Hypertension Reviews·Mar 14The Variability of Response to Amlodipine and Its Relation with the Angiotensinogen M235T Genotype among a Sample of Hypertensive Patients in JordanNon-randomized trial in 46 peopleAmlodipinePaper
Acta Physiologica·Mar 12Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence-The Protective Effect of ValsartanExperiments in miceValsartanPaper
European Journal of Heart Failure·Mar 2Implementation of guideline-directed medical therapy in patients with heart failure and obesity: European Journal of Heart Failure expert consensus documentReviewHeart failurePaper
European Journal of Internal Medicine·Feb 13Target systolic blood pressure in patients with left ventricular hypertrophyReviewLeft ventricular hypertrophyPaper
European Journal of Pharmacology·Feb 3CAMK1D and PI3 in low-density neutrophils are associated with the anti-hypertensive effects of valsartanNon-randomized trial in peopleValsartanPaper
Iranian Journal of Basic Medical Sciences·Jan 26Comparison of the therapeutic effects of sacubitril and valsartan combination versus metformin in experimentally induced polycystic ovary syndrome in ratsExperiments in ratsValsartanPaper
Clinical Hypertension·Jan 14Intensive blood pressure control to prevent major cardiovascular events in individuals with high-normal blood pressure (prehypertension): PRINT-TAHA9 randomized clinical trialRandomized trial in 235 peoplePrehypertensionPaper
Journal of the American College of Cardiology·Aug 26Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into GuidelinesReviewIndustry & policyPaper
Expert Opinion on Drug Safety·Dec 14Drug-induced dementia: a pharmacovigilance analysis of the FAERS databaseComputational studyDementiaPaper
Physiological Reports·Oct 24The protective effect of angiotensin II type I receptor blocker (valsartan) on behavioral impairment, NLRP3, BDNF, and oxidative stress in the brain tissue of ovariectomized female ratsExperiments in 32 ratsValsartanPaper
Biomacromolecules·Aug 26Co-Delivery of Valsartan and Metformin from a Thermosensitive Hydrogel-Nanoparticle System Promotes Collagen Production in Proliferating and Senescent Primary Human Dermal FibroblastsExperiments in human cellsValsartanPaper
European Journal of Pharmacology·Jul 6Effects of sacubitril-valsartan on aging-related cardiac dysfunctionExperiments in ratsSacubitril + valsartanPaper
European Journal of Internal Medicine·Aug 31Renin-angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registryCohort study of 5,769 peopleAtrial fibrillationPaper
Drugs & Aging·Jul 15Guideline-Directed Medical Therapies for Heart Failure with a Reduced Ejection Fraction in Older Adults: A Narrative Review on Efficacy, Safety and TimelinessReviewHeart failure with reduced ejection fractionPaper
Hypertension·Jun 23Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm HgCohort study of 13,803 peopleLeft ventricular hypertrophyPaper